Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
Krzysztof Dyrbuś,Mariusz Gąsior,Piotr Desperak,Przemysław Trzeciak,Jolanta Nowak,Peter E. Penson,Tadeusz Osadnik,Maciej Banach +7 more
Reads0
Chats0
TLDR
In this article, the authors identify subgroups of patients at the highest risk of death following myocardial infarction (MI) that might be considered as extremely high CVD risk.About:
This article is published in Atherosclerosis.The article was published on 2021-08-13 and is currently open access. It has received 12 citations till now. The article focuses on the topics: Myocardial infarction & Coronary artery disease.read more
Citations
More filters
Journal ArticleDOI
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
David Marais,Zeljko Reiner,Matteo Pirro,Manfredi Rizzo,Alexandros Sachinidis,Dan Gaita,Mohsen Mazidi,Daniel Pella,G.B. John Mancini,Stephan von Haehling,Maciej Banach,Julio Acosta,Mutaz Alkhnifsawi,Fahad Alnouri,Fahma Amar,Atanas G. Atanasov,G. Bajraktari,Sonu Bhaskar,Ibadete Bytyçi,Bojko Bjelakovic,Eric Bruckert,Alberto Cafferata,Richard Ceska,Arrigo F G Cicero,Xavier Collet,Magdalena Daccord,Olivier S. Descamps,Dragan Djuric,Ronen Durst,Marat V. Ezhov,Zlatko Fras,Adrian V. Hernandez,Steven P. Jones,Jacek Jerzy Jozwiak,N. Kakauridze,A. Kallel,Niki Katsiki,Amit Khera,Karam Kostner,Raimondas Kubilius,Gustavs Latkovskis,A. David Marais,Seth S. Martin,Julio A. Martínez,Dimitri P. Mikhailidis,Erkin M. Mirrakhimov,André R. Miserez,Olena Mitchenko,N.P. Mitkovskaya,Patrick M. Moriarty,Seyed Mohammad Nabavi,Devaki Nair,Demosthenes B. Panagiotakos,György Paragh,Peter E. Penson,Zaneta Petrulioniene,Arman Postadzhiyan,Raman Puri,Ashraf Reda,Dina Radenkovic,Michael Robert Rakowski,Jemaa Riadh,Dimitri Richter,Massimiliano Ruscica,Amirhossein Sahebkar,Naveed Sattar,Maria-Corina Serban,Abdullah Shehab,Aleksandr B Shek,Cesare R. Sirtori,Claudia Stefanutti,Tomasz Tomasik,Peter P. Toth,Margus Viigimaa,Pedro Valdivielso,Dragos Vinereanu,Branislav Vohnout,Michal Vrablík,Nathan D. Wong,Hung-I Yeh,Ji Zhisheng,Andreas Zirlik +81 more
TL;DR: A step‐by‐step patient‐centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long‐term compliance with lipid‐lowering therapy is presented.
Journal ArticleDOI
Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’ opinion. The compromise between EBM and possibilities in healthcare
Maciej Banach,Jarosław Kaźmierczak,P. Mitkowski,Krystian Wita,Marlena Broncel,Mariusz Gąsior,Marek Gierlotka,R.G. Gil,Piotr Jankowski,Maciej Niewada,Adam Witkowski +10 more
TL;DR: The fastest way to have inclisiran available for the polish patients, with the necessary changes of the existing drug program for PCSK9 inhibitors (B-101), is indicated, explaining why it is the optimal way, and why, taking into account available EBM data (the ORION program), inclisIRan should be added to this program.
Journal ArticleDOI
Extreme cardiovascular risk-do we need a new risk category?
Journal ArticleDOI
Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective.
TL;DR: Dyslipidemia has been globally recognized, for almost seven decades, as one of the most important risk factors for the development and complications of atherosclerotic cardiovascular disease (ASCVD) as mentioned in this paper.
Journal ArticleDOI
Is the standardized phase angle a predictor of short- and long-term adverse cardiovascular events in patients with acute myocardial infarction? A cohort study.
Sandra Azevedo Queiroz,Maria Cristina Gonzalez,Alana Monteiro Bispo da Silva,Jálissa Karla de Araújo Costa,Carlos Diego Ramos de Oliveira,Iasmin Matias de Sousa,Ana Paula Trussardi Fayh +6 more
TL;DR: In this paper , the phase angle (PhA) has been measured by bioelectrical impedance analysis (BIA) to identify the quality of the cell membrane and the distribution of body fluids.
References
More filters
Journal ArticleDOI
Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey
Tomasz Zdrojewski,Marcin Rutkowski,Piotr Bandosz,Zbigniew Gaciong,Tadeusz Jędrzejczyk,Bogdan Solnica,Michał Pencina,Wojciech Drygas,Bogdan Wojtyniak,Tomasz Grodzicki,Jerzy Piwoński,Bogdan Wyrzykowski +11 more
TL;DR: The NATPOL 2011 Survey was a cross-sectional observational study aimed to assess the prevalence and control of CVD risk factors in Poland and its structure, including age groups and gender is almost identical to the structure of the adult population of Poland in 2010.
Journal ArticleDOI
Změny na úrovni populace zaměřené na podporu kardiovaskulárního zdraví
Torben Jørgensen,Simon Capewell,Eva Prescott,Steven Allender,Susana Sans,Tomasz Zdrojewski,Dirk De Bacquer,J. De Sutter,Oscar H. Franco,Susanne Løgstrup,Massimo Volpe,S. K. Malyutina,W. M M Verschuren,Diego Vanuzzo +13 more
TL;DR: The evidence is summarized and a number of structural strategies at international, national, and regional levels that in combination can substantially reduce CVD are recommended.
Journal ArticleDOI
Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009–2012 — nationwide AMI-PL database
Marek Gierlotka,Tomasz Zdrojewski,Bogdan Wojtyniak,Lech Poloński,Jakub Stokwiszewski,Mariusz Gąsior,Adam Kozierkiewicz,Zbigniew Kalarus,Łukasz Wierucki,Krzysztof Chlebus,Marian Zembala,Mirosław J Wysocki,Grzegorz Opolski +12 more
TL;DR: The major cause of higher mortality due to AMI in the Polish population is a high incidence of AMI, indicating a need for intensification of primary prevention programmes.
Journal ArticleDOI
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
Chiara Macchi,Maciej Banach,Alberto Corsini,Cesare R. Sirtori,Nicola Ferri,Massimiliano Ruscica +5 more
TL;DR: Interest has been expanded to areas not only limited to low-density lipoprotein cholesterol reduction but also investigating other non-lipid pathways raising cardiovascular risk, in particular inflammation associated to raised high-sensitivity C-reactive protein levels, not significantly affected by the present PCSK9 antagonists.
Journal ArticleDOI
Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study.
Gabriel C. Brooks,Byron K. Lee,Rajni K. Rao,Feng Lin,Daniel P. Morin,Daniel P. Morin,Steven Zweibel,Alfred E. Buxton,Mark J. Pletcher,Eric Vittinghoff,Jeffrey E. Olgin +10 more
TL;DR: A model using clinical variables present at the time of MI can help predict EF recovery and in patients with severe systolic dysfunction following acute MI with an EF ≤35%, 57% had EF recovery to >35%.